Friday, May 1, 2026

Discover the Breakthrough: Daewoong’s CleanCol Tablet Reduces Dosage for Effective Colon Cleansing

Daewoong Pharmaceutical's Cleancol Tab. shows effective bowel cleansing with fewer tablets, improving patient adherence during colonoscopy prep.

THE $5 DEATH TRAP: Your Cheap Temu Hair Dryer Failed Safety Tests—Don’t Risk A House Fire!

A recent investigation found that several online-purchased electronics, including hair dryers and fans, fail U.S. safety standards.

Exploring the Future: HD Hyundai’s Collaboration with U.S. Naval Academy on Shipbuilding Innovations

HD Hyundai hosted U.S. Naval Academy midshipmen for a tour, showcasing advanced shipbuilding technologies and fostering collaboration.

Tag: biopharmaceuticals

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

GC Biopharma Corp breaks its fourth-quarter deficit with ALYGLO's success, achieving $106M in annual revenue and plans for future growth.

Unlocking Opportunities: 2025 Bio GMP Training Program Launches at Daejeon University

Daejeon University launched the 2025 Winter BioRG Training Program for biopharmaceuticals, featuring industry experts and hands-on sessions.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

2026: South Korea’s Advanced Regenerative Medicine R&D Investment Expands – What You Need to Know!

The Ministry of Health and Welfare aims to boost investments in advanced regenerative medicine R&D and improve research infrastructure in South Korea.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.